Epigenomics AG announces conversion result of the first conversion period of the mandatory convertible bond 2021/2024   Berlin (Germany) and San Diego (U.S.A.), April 20, 2021 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that convertible bonds with a nominal value of EUR 4,357,606.00 have been converted i [ … ]

Study reported in BMC Gastroenterology demonstrates significantly better performance characteristics of Epigenomics' liver cancer panel compared to the current standard of care for the early detection of hepatocellular carcinoma (HCC) in patients with liver cirrhosis The Epigenomics next generation sequencing (NGS) liver cancer panel plus alpha-f [ … ]

Epigenomics AG: Dr. Garces transitions to Company Advisor Berlin (Germany) and San Diego, CA (USA), January 27, 2021 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that Dr. Jorge Garces, President and Chief Scientific Officer is resigning as an Executive Board member effective January 31, 2021. Dr. Garces  [ … ]

Epigenomics AG Plans to Challenge NCD Decision and Unveils Its Next Generation Liquid Biopsy Test for Colorectal Cancer Screening Company evaluating all options to challenge CMS' decision to non-cover the Epi proColon test New blood-based test demonstrates performance characteristics that would satisfy the latest sensitivity and specificity requ [ … ]

U.S. Centers for Medicare & Medicaid Services publish negative NCD for Epi proColon Berlin, January 19, 2021 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that the U.S. Centers for Medicare & Medicaid Services (CMS) have issued a negative reimbursement decision in connection with the National Cover [ … ]

NOT TO BE PUBLISHED, DISSEMINATED OR PASSED ON TO OR WITHIN THE UNITED STATES OF AMERICA, CANADA, JAPAN AND AUSTRALIA Publication of inside information pursuant to Article 17 MAR Epigenomics AG issues mandatory convertible bond in the amount of up to EUR 5.5 million Berlin, Germany, January 7, 2021 - The Executive Board of Epigenomics AG (Frankf [ … ]